Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | DNM1 | Q05193 | 8/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Octane SCHEMBL4077297 | 1.00 | TSHR (0.67) | TSHRTHRBALDH1A1DNM1LMNA | |
| Hexadecane SCHEMBL2833679 | 1.00 | TSHR (0.67) | TSHRTHRBALDH1A1DNM1LMNA | |
| Chloroform SCHEMBL28294775 | 1.00 | TSHR (0.67) | TSHRTHRBALDH1A1DNM1LMNA | |
| Heptane SCHEMBL11026529 | 0.96 | TSHR (0.61) | TSHRTHRBALDH1A1DNM1LMNA | |
| Hexane SCHEMBL4333874 | 0.96 | TSHR (0.58) | TSHRTHRBALDH1A1DNM1LMNA | |
| Hexane SCHEMBL9244722 | 0.96 | TSHR (0.58) | TSHRTHRBALDH1A1DNM1LMNA | |
| Hexane SCHEMBL3782949 | 0.96 | TSHR (0.58) | TSHRTHRBALDH1A1DNM1LMNA | |
| Hexane SCHEMBL4330650 | 0.96 | TSHR (0.58) | TSHRTHRBALDH1A1DNM1LMNA | |
| Hexane SCHEMBL55152 | 0.96 | TSHR (0.58) | TSHRTHRBALDH1A1DNM1LMNA | |
| Hexane SCHEMBL4325387 | 0.96 | TSHR (0.58) | TSHRTHRBALDH1A1DNM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103664837-B | A kind of preparation method of high purity Cabazitaxel intermediate | BEIJING SUN-NOVO PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2016-01-20 | — | — | CN | claimed |
| CN-101921213-A | Method for synthesizing ketazine by hydrogen peroxide oxidation method | LIMING RES INST CHEMICAL IND | 2010-12-22 | — | — | CN | claimed |
| CN-1995084-A | Organic polymer graft modified nanometer titanium dioxide preparation method | UNIV ELECTRONIC SCIENCE & TECH (CN) | 2007-07-11 | — | — | CN | claimed |
| CN-1594495-A | Method for improving photoluminescence of nano anatase TiO#-[2] | UNIV ELECTRONIC SCIENCE & TECH (CN) | 2005-03-16 | — | — | CN | claimed |
| EP-0959138-B1 | Process for the preparation of Baccatin-III by enzymatic synthesis | INST BIOANALYTIK UMWELT TOXILO (DE) | 2004-09-29 | — | — | EP | claimed |
| US-20240172553-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT | CANON KABUSHIKI KAISHA (JP) | 2024-05-23 | — | — | US | disclosed |
| US-20240099135-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT | CANON KABUSHIKI KAISHA (JP) | 2024-03-21 | — | — | US | disclosed |
| EP-4332096-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT | CANON KABUSHIKI KAISHA (JP) | 2024-03-06 | — | — | EP | disclosed |
| WO-2024011218-A1 | POLYMERIC NANOPARTICLES FOR LONG ACTING DELIVERY OF A PEPTIDE AND METHODS OF MAKING AND USING THEREOF | BROWN UNIVERSITY (US) | 2024-01-11 | — | — | WO | disclosed |
| WO-2023238629-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE | キヤノン株式会社 | 2023-12-14 | — | — | WO | disclosed |
| US-20230403933-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT | CANON KABUSHIKI KAISHA (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230322691-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT | CANON KABUSHIKI KAISHA (JP) | 2023-10-12 | — | — | US | disclosed |
| US-4081532-A | FOR CONTROLLING COCCIDIOSIS; IMPROVING FEED EFFICIENCY IN RUMINANTS | PFIZER INC. (US) | 1978-03-28 | — | — | US | disclosed |
| US-4036845-A | Novel transient acyl derivatives of phenylbutazone | INTERX RESEARCH CORPORATION (US) | 1977-07-19 | — | — | US | disclosed |
| US-4015976-A | N-acetyl L-polychlorobenzamide herbicides | TEXACO DEVELOPMENT CORPORATION (US) | 1977-04-05 | — | — | US | disclosed |
| US-4001214-A | AMINOALKYL ETHERS OF 2,2'- AND 3,3'-DIHYDROXYBENZIL | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-01-04 | — | — | US | disclosed |
| US-3959370-A | HERBICIDE | JEFFERSON CHEMICAL COMPANY, INC. (US) | 1976-05-25 | — | — | US | disclosed |
| US-3957803-A | CERTAIN TRANSIENT PRO-DRUG FORMS OF PHENYLBUTAZONE | INTERX RESEARCH CORPORATION (US) | 1976-05-18 | — | — | US | disclosed |
| US-3956101-A | HIGH GRADE NEEDLES, BUBBLING NON-OXIDIZING GAS THROUGH REFORMED OIL | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JA) | 1976-05-11 | — | — | US | disclosed |
| US-3947404-A | CARDIAC THERAPY | BOEHRINGER MANNHEIM GMBH (DT) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240099135-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT | ARNT, NR2E3, CRY1 | TSHR 1656/4885THRB 1076/4885ALDH1A1 129/4885 |
| US-20230403933-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT | OR10J3, RPS19, ORC3 | TSHR 1006/4885THRB 1450/4885ALDH1A1 560/4885 |
| US-20230322691-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT | CCNT1, CCNE2, SCO2 | TSHR 3782/4885THRB 2093/4885ALDH1A1 240/4885 |
| US-20240172553-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT | NOM1, L1CAM, AP2M1 | TSHR 4074/4885THRB 3866/4885ALDH1A1 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.